A comparative analysis of the outcomes of patients with influenza or COVID-19 in a tertiary hospital in Belgium.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 04 04 2022
revised: 03 07 2022
accepted: 18 07 2022
pubmed: 10 8 2022
medline: 14 9 2022
entrez: 9 8 2022
Statut: ppublish

Résumé

The COVID-19 pandemic has emerged as a global health problem, associated with high morbidity and mortality rates. The aim of this study was to compare the outcomes of hospitalized patients with COVID-19 or with seasonal influenza in a teaching hospital in Belgium. In this retrospective, single-center cohort study, 1384 patients with COVID-19 and 226 patients with influenza were matched using a propensity score with a ratio of 3:1. Primary outcomes included admission to intensive care unit (ICU), intubation rates, hospital length of stay, readmissions within 30 days and in-hospital mortality. Secondary outcomes included pulmonary bacterial superinfection, cardiovascular complications and ECMO. Based on the analysis of the matched sample, patients with influenza had an increased risk of readmission within 30 days (Risk Difference (RD): 0.07, 95% CI: 0.03 to 0.11) and admission to intensive care unit (RD: 0.09, 95% CI: 0.03 to 0.15) compared with those with COVID-19. Patients with influenza had also more pulmonary bacterial superinfections (46.2% vs 7.4%) and more cardiovascular complications (32% vs 3.9%) than patients with COVID-19.However, a two-fold increased risk of mortality (RD: -0.10, 95% CI: 0.15 to -0.05) was observed in COVID-19 compared to influenza. ECMO was also more required among the COVID-19 patients who died than among influenza patients (5% vs 0%). COVID-19 is associated with a higher in-hospital mortality compared to influenza infection, despite a high rate of ICU admission in the influenza group. These findings highlighted that the severity of hospitalized patients with influenza should not be underestimated.

Identifiants

pubmed: 35944762
pii: S1341-321X(22)00208-2
doi: 10.1016/j.jiac.2022.07.012
pmc: PMC9356567
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1489-1493

Informations de copyright

Copyright © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Références

JAMA Netw Open. 2020 Aug 3;3(8):e2017527
pubmed: 32789512
J Infect Public Health. 2020 Dec;13(12):1797-1804
pubmed: 33121906
CMAJ. 2021 Mar 22;193(12):E410-E418
pubmed: 33568436
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
Euro Surveill. 2020 Mar;25(11):
pubmed: 32186278
Int J Infect Dis. 2021 Feb;103:316-322
pubmed: 33279652
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
Clin Infect Dis. 2014 Jul 15;59(2):252-5
pubmed: 24748521
JAMA Intern Med. 2020 Aug 1;180(8):1045-1046
pubmed: 32407441
Ann Am Thorac Soc. 2021 Apr;18(4):632-640
pubmed: 33183067
Clin Infect Dis. 2021 May 18;72(10):e533-e541
pubmed: 32820807
Rev Med Virol. 2021 May;31(3):e2179
pubmed: 33035373
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Sep 11;11:552909
pubmed: 33013925
BMJ. 2020 Dec 15;371:m4677
pubmed: 33323357
Crit Care. 2020 Jul 9;24(1):410
pubmed: 32646494
BMJ. 2020 May 22;369:m1985
pubmed: 32444460

Auteurs

Silvio Wallemacq (S)

Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium. Electronic address: Silvio.wallemacq@gmail.com.

Celestin Danwang (C)

Epidemiology and Biostatistics Unit, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Anais Scohy (A)

Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Leila Belkhir (L)

Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Julien De Greef (J)

Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Benoit Kabamba (B)

Department of Laboratory Medicine, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.

Jean Cyr Yombi (JC)

Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium. Electronic address: Jean.yombi@saintluc.uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH